Acorda Therapeutics reviews AMPYRA gross sales of $3.


Acorda’s partner Biogen Idec, which is responsible for commercialization beyond your U.S., provides filed regulatory applications for Fampridine prolonged-release tablets in regions including European countries, Canada, Switzerland, New and Australia Zealand. GGF2 In March, Acorda submitted an Investigational New Medication application for GGF2 as a therapy for heart failure. The Company programs to initiate a Stage 1 single ascending dosage clinical trial in patients with heart failing in mid-2010. Corporate Update Lauren Sabella became a member of the ongoing organization as Executive Vice President of Commercial Development, and Adrian L. Rabinowicz, M.D., FAAN, joined as Senior Vice President and Mind, Medical Affairs..ExxonMobil has been a great partner to bettering the lives of those surviving in Africa, said Africare President Darius Mans. The company’s contributions – including not just funds, but their initiatives to provide on-the-floor support, lend business expertise and raise the world’s awareness of the scourge of malaria – have saved countless lives on the continent. The brand new grants, which total $1,425,000, will enable thousands of additional children and families in Africa to get the necessary care for managing malaria. The new pilot Malaria Prevention Promotion in Nigeria shall reach a lot more than 75,000 regional contractors and suppliers and their families in the Delta area of the country with a bundle of malaria prevention, vector and treatment control services. The program also contains a media campaign to educate thousands more folks in the same region about malaria prevention.